As we all know, China has become the second largest biomedical market in the world. However, in recent years, under the influence of a series of policies such as consistency evaluation and quantity procurement, the domestic pharmaceutical market environment has undergone drastic changes, and international development has become an important starting point for promoting the restructuring of China's pharmaceutical industry and the transformation and upgrading of pharmaceutical companies.

In the process of internationalization, on the one hand, the growth of the pharmaceutical market in developed countries and regions such as Europe and the United States has slowed down, the technical regulations are strict, and the difficulty of entry has increased; on the other hand, the potential of emerging markets is huge. According to statistics, 80% of the growth of pharmaceutical sales in the future comes from emerging markets. By 2022, emerging markets will account for 56% of the global pharmaceutical market, and in 2012 this figure was only 49%. The “One Belt, One Road” initiative provides a historical opportunity for international cooperation between domestic and emerging market countries.